دورية أكاديمية
Trapping Tribbles: Nanobody-assisted structure of the TRIB2 pseudokinase.
العنوان: | Trapping Tribbles: Nanobody-assisted structure of the TRIB2 pseudokinase. |
---|---|
المؤلفون: | Santana FR; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA., Linossi EM; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA., Jura N; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: natalia.jura@ucsf.edu. |
المصدر: | Structure (London, England : 1993) [Structure] 2022 Nov 03; Vol. 30 (11), pp. 1465-1467. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Comment |
اللغة: | English |
بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101087697 Publication Model: Print Cited Medium: Internet ISSN: 1878-4186 (Electronic) Linking ISSN: 09692126 NLM ISO Abbreviation: Structure Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2000- : Cambridge, Mass. : Cell Press Original Publication: London : Current Biology, c1993- |
مواضيع طبية MeSH: | Calcium-Calmodulin-Dependent Protein Kinases*/metabolism , Intracellular Signaling Peptides and Proteins*/genetics , Intracellular Signaling Peptides and Proteins*/metabolism, Humans ; Protein Serine-Threonine Kinases/genetics ; Signal Transduction |
مستخلص: | TRIB2, a member of the human Tribbles pseudokinase family, functions as a molecular scaffold in diverse signaling pathways. In this issue of Structure, Jamieson et al. report the first high-resolution structure of TRIB2 bound to a nanobody that offers insights into its "active-like" state. Competing Interests: Declaration of interests N.J. is a founder, shareholder, and consultant of Rezo Therapeutics; a member and a shareholder of Scientific Advisory Board of Sudo Therapeutics and Type6 Therapeutics; and a member of Scientific Advisory Board of Novartis Oncology. (Copyright © 2022 Elsevier Ltd. All rights reserved.) |
التعليقات: | Comment on: Structure. 2022 Nov 3;30(11):1518-1529.e5. (PMID: 36108635) |
معلومات مُعتمدة: | R35 GM139636 United States GM NIGMS NIH HHS |
المشرفين على المادة: | EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases) 0 (Intracellular Signaling Peptides and Proteins) EC 2.7.11.1 (Protein Serine-Threonine Kinases) EC 2.7.11.17 (TRIB2 protein, human) |
تواريخ الأحداث: | Date Created: 20221104 Date Completed: 20221108 Latest Revision: 20221201 |
رمز التحديث: | 20240628 |
DOI: | 10.1016/j.str.2022.10.006 |
PMID: | 36332608 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1878-4186 |
---|---|
DOI: | 10.1016/j.str.2022.10.006 |